Predicting infection risk from resistant bacteria in blood cancer patients
Part of Blood & lymphatic clinical trials.
This study looks at patients with blood cancers who may carry bacteria that are resistant to many antibiotics. It aims to find which patients are more likely to get sick from these bacteria, so doctors can better protect them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer such as leukemia, lymphoma, or myeloma.
- You are about to receive treatment like chemotherapy, a stem cell transplant, or CAR-T therapy.
- Your treatment is expected to lower your white blood cell count (neutropenia) in the next few days.
- You have not already had these resistant bacteria before.
- You are not too ill to participate and can understand the study.
- Your doctor agrees you can take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at when to start antibiotics early for blood cancer patients who may be carrying resistant bacteria (that are hard to treat). It aims to find the best time to treat these infections to improve outcomes.
This study looks at why some healthy people carry resistant bacteria in their gut (called ESBL-producing bacteria). Researchers will collect stool and urine samples and ask about your daily life to find possible risk factors. You won't receive any treatment, but your participation can help scientists understand how to prevent the spread of these bacteria.
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
This study looks at how the bacteria in your gut change during cancer treatment (and during some blood stem cell transplants). It may help researchers understand why some people respond differently and guide better future treatment.
This study watches how infections grow and respond to treatment in cancer patients who may have sepsis. It aims to find better ways to diagnose and monitor sepsis early, which could improve care and outcomes.
This study looks at the genetic makeup of hard-to-treat bacteria (carbapenem-resistant Enterobacterales) that cause infections in cancer patients at Sohag Oncology Center. By understanding these bacteria, doctors may better target treatments and improve patient care.
Hear when a new Hemato-oncologic Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.